Optimizing management strategies for T4b esophageal cancer: the role of TEVAR in multimodal treatment approaches.

Authors

Nikolaos Koliakos, Andrianos-Serafeim Tzortzis, Dimitrios Papakonstantinou, Evgenia Mela, Natasha Hasemaki, Michail Peroulis, Anargyros Bakopoulos, Dimitrios Schizas

Published in

Scandinavian journal of gastroenterology. Pages 1-7. Oct 10, 2026. Epub Oct 10, 2026.

Abstract

T4b esophageal cancer with aortic invasion remains a major therapeutic challenge because treatment-related tumor regression may precipitate aortoesophageal fistula formation and catastrophic hemorrhage. While chemoradiotherapy is the backbone of disease control, the role of thoracic endovascular aortic repair (TEVAR) as prophylaxis or bridge therapy within a multimodal treatment strategy is increasingly recognized.
This narrative review synthesizes current evidence on the use of TEVAR in T4b esophageal cancer. Relevant clinical studies, reviews and guideline documents were evaluated qualitatively, with emphasis on treatment sequencing, bleeding prevention, resectability and oncologic outcomes.
Available retrospective studies and systematic reviews suggest that elective TEVAR may reduce the risk of major bleeding complications and facilitate subsequent esophagectomy in selected patients. Elective TEVAR was associated with higher rates of subsequent esophageal resection and fewer complications than salvage TEVAR. Moreover, elective TEVAR followed by esophagectomy, ameliorates significantly patients survival. These findings support the potential role of elective TEVAR within multimodal treatment strategies, although the available evidence remains predominantly retrospective and is subject to selection bias and heterogeneity in patient selection and treatment.
TEVAR may represent a useful adjunct in the multimodal management of selected patients with T4b esophageal cancer and aortic involvement. In carefully selected patients, elective TEVAR may reduce the risk of catastrophic hemorrhage and facilitate subsequent curative-intent treatment, including conversion esophagectomy, although prospective evidence defining its optimal indications and timing remains lacking.

PMID:
42856077
Bibliographic data and abstract were imported from PubMed on 10 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.